Therapeutic checkpoint antibodies blocking programmed death receptor 1/programmed death ligand 1 (PD-L1) signaling have radically improved clinical outcomes in cancer. However, the regulation of PD-L1 expression on tumor cells is still poorly understood. Here we show that intratumoral copper levels influence PD-L1 expression in cancer cells. Deep analysis of the The Cancer Genome Atlas database and tissue microarrays showed strong correlation between the major copper influx transporter copper transporter 1 (CTR-1) and PD-L1 expression across many cancers but not in corresponding normal tissues. Copper supplementation enhanced PD-L1 expression at mRNA and protein levels in cancer cells and RNA sequencing revealed that copper regulates key signaling pathways mediating PD-L1–driven cancer immune evasion. Conversely, copper chelators inhibited phosphorylation of STAT3 and EGFR and promoted ubiquitin-mediated degradation of PD-L1. Copper-chelating drugs also significantly increased the number of tumor-infiltrating CD8+ T and natural killer cells, slowed tumor growth, and improved mouse survival. Overall, this study reveals an important role for copper in regulating PD-L1 and suggests that anticancer immunotherapy might be enhanced by pharmacologically reducing intratumor copper levels. Significance: These findings characterize the role of copper in modulating PD-L1 expression and contributing to cancer immune evasion, highlighting the potential for repurposing copper chelators as enhancers of antitumor immunity.
12 June 2009 in Journal of Agricultural and Food Chemistry
Well-known for their antioxidant properties, polyphenols are naturally occurring compounds containing one or more phenol groups. A high dietary intake of polyphenols has been linked to a reduced incidence of a number of diseases, including cancer, cardiovascular diseases, diabetes, osteoporosis and neurodegenerative diseases. Furthermore, in vitro and in vivo studies show the potential for polyphenols as therapeutic agents with cardioprotective, antimicrobial, anticancer, neuroprotective, and antidiabetic effects demonstrated. Despite their impressive therapeutic effects, polyphenols suffer from a number of drawbacks, including instability when exposed to light, heat and basic conditions; poor bioavailability; rapid metabolism; and poor membrane permeability. These drawbacks limit the clinical applications of polyphenols. Polymers and other macromolecules are well-known for their ability to stabilise and improve the bioavailability of therapeutic agents. A number of macromolecular systems have been developed that stabilise polyphenols whilst enhancing their therapeutic effects, including direct polymerisation of polyphenol monomers via step-growth, free radical and enzyme catalysed reactions; and conjugation with macromolecules via enzyme grafting, free-radical grafting, esterification and amidation. In this review, we will detail the key techniques employed to stabilise polyphenols with macromolecules and provide examples of each technique.